SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Kelly DL, Conley RR. Sexuality and schizophrenia: a review. Schizophr. Bull. 2005; 30: 767769.
  • 2
    Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum. Psychopharmacol. Clin. Exp. 2008; 23: 201209.
  • 3
    Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 22912314.
  • 4
    Montejo AL. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur. Neuropsychopharmacol. 2008; 18: S108S114.
  • 5
    Freeman B, Levy W, Gorman JM. Successful monotherapy treatment with aripiprazole in a patient with schizophrenia and prolactinoma. J. Psychiatr. Pract. 2007; 13: 1204.
  • 6
    Staller J. The effect of long-term antipsychotic treatment on prolactin. J. Child Adolesc. Psychopharmacol. 2006; 16: 317326.
  • 7
    Hanssens I, L'Italien G, Loze JY, Marcus RN, Pans M, Kerselaers W. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry 2008; 22: 95106.
  • 8
    National Institute of Mental Health. CGI: clinical global impressions. In: GuyW (ed.). ECDEU Assessment Manual of Psychoparmacology, Revised. NIMH, US Department of Health, Education and Welfare Publication (ADM), Rockville, MD, 1976; 7638.
  • 9
    McGahuey CA, Gelenberg AJ, Laukes CA et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J. Sex Marital Ther. 2000; 26: 2540.
  • 10
    Bostwick JR, Guthrie SK, Ellingrod VL. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009; 29: 6473.
  • 11
    Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28 (Suppl. 2): 5568.